Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) together With Chemotherapy surely Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative carcinoma Whose Tumors Express PD-L1 (CPS ?10)
The Pharma Data
SEPTEMBER 28, 2021
“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Merck has the industry’s largest immuno-oncology clinical research program.
Let's personalize your content